Evidence map›Paper›PMID 34885227›Full record

ArticleCancers2021

Efficacy, Outcome, and Safety of Elderly Patients with Glioblastoma in the 5-ALA Era: Single Center Experience of More Than 10 Years.

Barbara Kiesel, Lisa I Wadiura, Mario Mischkulnig, Jessica Makolli, Veronika Sperl, Martin Borkovec, Julia Freund, Alexandra Lang, Matthias Millesi, Anna S Berghoff and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Glioblastoma Therapy: Past, Present and Future.International journal of molecular sciences · 2024
    Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Barbara KieselDepartment of Neurosurgery, Medical University Vienna, 1090 Vienna, Austria.ORCID 0000-0003-0939-9831
Lisa I WadiuraDepartment of Neurosurgery, Medical University Vienna, 1090 Vienna, Austria.ORCID 0000-0002-9227-461X
Mario MischkulnigDepartment of Neurosurgery, Medical University Vienna, 1090 Vienna, Austria.ORCID 0000-0001-5478-0792
Jessica MakolliDepartment of Neurosurgery, Medical University Vienna, 1090 Vienna, Austria.
Veronika SperlDepartment of Neurosurgery, Medical University Vienna, 1090 Vienna, Austria.
Martin BorkovecDepartment of Neurosurgery, Medical University Vienna, 1090 Vienna, Austria.
Julia FreundDepartment of Neurosurgery, Medical University Vienna, 1090 Vienna, Austria.
Alexandra LangDepartment of Neurosurgery, Medical University Vienna, 1090 Vienna, Austria.ORCID 0000-0003-1099-8989
Matthias MillesiDepartment of Neurosurgery, Medical University Vienna, 1090 Vienna, Austria.ORCID 0000-0001-9503-4278
Anna S BerghoffDepartment of Medicine I, Clinical Division of Oncology, Medical University of Vienna, 1090 Vienna, Austria.
Julia FurtnerDepartment of Biomedical Imaging and Image-Guided Therapy, Medical University Vienna, 1090 Vienna, Austria.
Adelheid WoehrerDepartment of Neurology, Institute of Neuropathology and Neurochemistry, Medical University Vienna, 1090 Vienna, Austria.ORCID 0000-0001-8435-8189
Georg WidhalmDepartment of Neurosurgery, Medical University Vienna, 1090 Vienna, Austria.ORCID 0000-0001-6014-0273
Medical University of Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn the next decades, the incidence of patients with glioblastoma (GBM) will increase due to the growth of the elderly population. Fluorescence-guided resection using 5-aminolevulinic acid (5-ALA) is widely applied to achieve maximal safe resection of GBM and is identified as a novel intraoperative marker for diagnostic tissue during biopsies. However, detailed analyses of the use of 5-ALA in resections as well as biopsies in a large elderly cohort are still missing. The aim of this study was thus to investigate the efficacy, outcome, and safety of surgically- treated GBM in the 5-ALA era in a large elderly cohort.

methodsAll GBM patients aged 65 years or older who underwent neurosurgical intervention between 2007 and 2019 were included. Data on 5-ALA application, intraoperative fluorescence status, and 5-ALA-related side effects were derived from our databank. In the case of resection, the tumor resectability and the extent of resection were determined. Potential prognostic parameters relevant for overall survival were analyzed.

results272 GBM patients with a median age of 71 years were included. Intraoperative 5-ALA fluorescence was applied in most neurosurgical procedures (

conclusionsOur data of this large elderly cohort demonstrate the clinical utility and safety of 5-ALA fluorescence in GBM for improved tumor visualization in both resections as well as biopsies. Therefore, we recommend the use of 5-ALA not only in resections, but also in open/stereotactic biopsies to optimize the neurosurgical management of elderly GBM patients.

Indexed as

5-aminolevulinic acidbiopsyelderly patientsglioblastomaresection

Identifiers

PMID34885227
PMCPMC8657316
OpenAlexW4200572943

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.